Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
American chemical industry news
(page 2)
23 October 2025
Elkem Q3 2025: Strong Operations and Cost Improvements Boost Results
EBITDA fell 33% YoY due to low sales prices. Silicones division under review for sale. EU and US trade measures may impact future performance.
23 October 2025
INEOS Alerts Europe on Risk to Medicine Supply
European BDO production is threatened by cheap imports from China, risking jobs and medicine supply chains. Urgent EU action is needed to block unfair competition and protect local industry.
22 October 2025
Symrise Invests in Cellibre to Boost Innovation in Taste and Cosmetic Markets
Symrise gains access to Cellibre's fermentation tech for scalable, sustainable ingredient production, enhancing supply chain resilience and aligning with sustainability goals.
22 October 2025
EnviTec Biogas AG Wins 2025 Energy Vision Leadership Award
EnviTec recognized for advancing clean energy and circular economy, with notable projects like Germany's largest bio-LNG plant, Güstrow, highlighting economic and environmental benefits.
22 October 2025
WuXi Biologics Joins Hang Seng Corporate Sustainability Index
Recognized for ESG excellence, the company advances sustainable practices and aligns with global initiatives, earning multiple sustainability accolades and maintaining a strong industry presence.
21 October 2025
Takeda Partners with Innovent on Oncology Medicines
Takeda gains rights to two late-stage cancer drugs and an option for an early-stage program, focusing on global development and commercialization outside Greater China.
How does the American chemical industry perform?
Find out with
chemXplore Analytics
Learn more
21 October 2025
BASF and IFF Collaborate on Enzyme and Polymer Innovation
The collaboration aims to develop sustainable enzyme and polymer technologies for cleaning and personal care, enhancing performance and reducing environmental impact.
21 October 2025
Port of Antwerp-Bruges: Mixed Results Amid Volatile Market
Container traffic stabilizes, bulk declines due to global uncertainty. US tariffs impact exports. European chemical sector faces challenges. RoRo and US trade show growth.
20 October 2025
Merck Begins $3B Pharmaceutical Facility Construction in Virginia
Merck invests $70B in U.S. manufacturing and R&D, creating 500+ full-time and 8,000 construction jobs in Virginia, enhancing biopharmaceutical innovation and domestic production.
20 October 2025
Novo Nordisk to Present Oral Semaglutide and Obesity Data at ObesityWeek 2025
New data on oral semaglutide and CagriSema will be presented, focusing on weight loss efficacy, cardiometabolic health, and women's health in obesity management.
20 October 2025
Roche's Gazyva Approved by FDA for Lupus Nephritis Treatment
FDA approves Gazyva for lupus nephritis, showing superior results in trials, offering a new treatment option to prevent kidney disease progression.
19 October 2025
Raludotatug Deruxtecan Shows 50.5% Response in Platinum-Resistant Ovarian Cancer, Reports Daiichi Sankyo and Merck
Raludotatug deruxtecan achieved a 50.5% response rate in phase 2 for platinum-resistant ovarian cancer, with a 5.6 mg/kg dose selected for phase 3.
18 October 2025
Genmab Reports Positive Phase 1/2 Trial Results for Rina-S in Advanced Endometrial Cancer
Rina-S shows 50% response rate in advanced endometrial cancer trial; FDA grants Breakthrough Therapy Designation.
18 October 2025
Merck's KEYTRUDA Plus Chemotherapy Reduces Disease Progression Risk in Platinum-Resistant Ovarian Cancer
KEYTRUDA with chemotherapy shows significant survival benefits in platinum-resistant ovarian cancer, leading to FDA priority review for expanded use.
17 October 2025
Roche Unveils Phase III Data for Vamikibart in Uveitic Macular Edema
Vamikibart shows promise in treating UME, with significant vision improvements in trials, offering a non-steroid alternative with fewer side effects.
17 October 2025
FDA Approves Novo Nordisk's Oral Semaglutide for CV Risk Reduction in High-Risk Type 2 Diabetes Adults
Oral semaglutide reduces major cardiovascular events in high-risk type 2 diabetes patients, showing a 14% risk reduction over 4 years, with consistent safety profile.
17 October 2025
Roche's Gazyva/Gazyvaro Gains EU CHMP Nod for Lupus Nephritis
CHMP backs Gazyva/Gazyvaro for lupus nephritis, showing superior renal response in trials. Awaiting European Commission decision.
17 October 2025
Mitsubishi Gas Chemical and Cirena Agree on Japan Distribution for Long-Chain RNA
MGC and Cirena to negotiate exclusive Japan distribution for long-chain RNA, enhancing MGC's nucleic acid pharmaceutical efforts.
16 October 2025
BASF Launches High-Purity Isobionics® Natural Lime Flavor Ingredient
Isobionics® Natural alpha-Farnesene 95 offers high purity for lime applications, is fermentation-based, and meets EU/US food regulations. Suitable for beverages, sweets, and citrus flavors.
16 October 2025
Aptar Digital Health's HeroTracker Sense Gains FDA 510(k) Clearance
HeroTracker Sense, a Bluetooth sensor for inhalers, gets FDA clearance, enhancing asthma and COPD management with real-time tracking and personalized support for patients aged 12 and above.
16 October 2025
Johnson & Johnson's AKEEGA® Gets FDA Priority Review for BRCA-Mutated Prostate Cancer
FDA grants Priority Review to AKEEGA® for BRCA-mutated prostate cancer, showing reduced progression risk and improved outcomes in Phase 3 study.
16 October 2025
Merck's KEYNOTE-B96 Trial Shows Improved Survival in Platinum-Resistant Ovarian Cancer
The trial showed improved overall survival with KEYTRUDA in platinum-resistant ovarian cancer, with consistent safety and no new signals. Results to be presented at a future medical meeting.
15 October 2025
Novo Nordisk Acquires Rights to Omeros' MASP-3 Inhibitor Zaltenibart
Zaltenibart, a MASP-3 inhibitor, targets rare blood and kidney disorders. Omeros receives up to $2.1 billion, plus royalties. Novo Nordisk plans global phase 3 trials.
15 October 2025
BASF Launches Ameriflor Calm for Sensitive Skin
Ameriflor Calm, a plant-based ingredient, enhances skin resilience, reduces redness, and is sustainably sourced and produced using renewable energy.
14 October 2025
BASF Launches Sustainable Nylon 6 Solutions in North America
BASF introduces Ultramid LowPCF and BMB, reducing carbon footprints by up to 50% using renewable natural gas, supporting sustainability without altering existing operations.
14 October 2025
BASF's Zorina Fungicide Gains EPA Approval
Zorina fungicide, combining Endura and Revysol, is approved by the EPA to combat white mold in soybeans, canola, and dry beans, enhancing yield potential.
14 October 2025
Merus Publishes Abstract on Petosemtamab for Metastatic Colorectal Cancer at AACR-NCI-EORTC Conference
Petosemtamab shows antitumor activity and manageable safety in mCRC trials, with ongoing data updates to be presented at the conference.
14 October 2025
Genmab Reports Q3 2025 DARZALEX Sales of $3.67 Billion
Genmab earns royalties from DARZALEX sales, with $2.09B in the U.S. and $1.58B globally. The company focuses on innovative antibody therapeutics for cancer and serious diseases.
14 October 2025
BP Q3 2025 Trading Update
Upstream production rises, gas trading average, oil trading weak. Asset impairments expected. Net debt stable at $26B. Brent at $69.13/bbl, Henry Hub at $3.07/mmBtu.
13 October 2025
Merus to Present Petosemtamab Data at AACR-NCI-EORTC Conference
Petosemtamab data in metastatic colorectal cancer to be presented in plenary and poster sessions at an upcoming conference.
← Previous
Next →
